Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: Wegovy’s solid new trial results; Lilly’s sales swing back; nothing off the table for new Bayer boss; new compliance crackdown in China; and McKinsey on AI.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 11 August 2023, including: Wegovy’s solid new trial results; Eli Lilly and Company’s sales swing back; nothing off the table for new Bayer AG boss; new compliance crackdown in China; and McKinsey on AI.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "SELECT: Novo Nordisk Comes Roaring Back" - Scrip, 8 Aug, 2023.)
(Also see "Lilly Sales Swing Back As Pandemic, Loss Of Exclusivity Pressures Recede" - Scrip, 9 Aug, 2023.)
(Also see "Nothing Off The Table For New Bayer Boss" - Scrip, 8 Aug, 2023.)
(Also see "Storm Coming? Commercial Compliance Crackdown Shocks China Pharma Industry" - Scrip, 8 Aug, 2023.)
(Also see "McKinsey Exec On Generative AI in R&D And Pharmacovigilance, Digital Twins" - Scrip, 7 Aug, 2023.)